Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS)

Harbor Capital Advisors Inc. purchased a new stake in shares of Merus (NASDAQ:MRUS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 42,287 shares of the biotechnology company's stock, valued at approximately $2,113,000. Harbor Capital Advisors Inc. owned approximately 0.06% of Merus as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MRUS. Allspring Global Investments Holdings LLC bought a new position in Merus during the 1st quarter valued at about $72,000. BNP Paribas Financial Markets increased its position in shares of Merus by 63.8% during the first quarter. BNP Paribas Financial Markets now owns 102,885 shares of the biotechnology company's stock worth $4,633,000 after purchasing an additional 40,060 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Merus by 160.7% during the 1st quarter. Quantbot Technologies LP now owns 7,300 shares of the biotechnology company's stock worth $329,000 after purchasing an additional 4,500 shares during the period. SG Americas Securities LLC acquired a new position in Merus during the 1st quarter worth about $108,000. Finally, Swiss National Bank lifted its stake in Merus by 1.9% during the first quarter. Swiss National Bank now owns 74,054 shares of the biotechnology company's stock worth $3,335,000 after purchasing an additional 1,400 shares during the last quarter. Institutional investors own 96.14% of the company's stock.

Merus Stock Up 1.0 %

NASDAQ:MRUS traded up $0.52 during trading hours on Tuesday, hitting $51.75. 251,121 shares of the company's stock traded hands, compared to its average volume of 692,646. The business's fifty day simple moving average is $50.81 and its two-hundred day simple moving average is $51.53. Merus has a 52 week low of $22.01 and a 52 week high of $61.61. The firm has a market cap of $3.53 billion, a P/E ratio of -13.10 and a beta of 1.12.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $67.00 price objective on shares of Merus in a report on Thursday, July 25th. Lifesci Capital upgraded Merus to a "strong-buy" rating in a research note on Monday, July 29th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 target price on shares of Merus in a report on Friday. Guggenheim raised their target price on Merus from $93.00 to $111.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Finally, UBS Group initiated coverage on Merus in a research note on Thursday, October 24th. They set a "buy" rating and a $72.00 price objective for the company. One analyst has rated the stock with a sell rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $86.70.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.